Webinar

From Transfection to Protein: Streamlining Transient Protein Expression with the eviCHO Expression Kit

Early discovery teams need to generate research-grade recombinant proteins more quickly and reproducibly, at the scale each project demands. Chinese Hamster Ovary (CHO) cells remain the gold standard for recombinant protein expression, but building and maintaining a reliable transient expression workflow in-house often means spending more time on troubleshooting than on science.

In this webinar, Evonik and evitria will introduce the eviCHO Expression Kit, a comprehensive, ready-to-use system designed to simplify transient protein expression while delivering exceptional results. Developed with evitria’s extensive expertise in CHO-based protein expression, the kit brings together all the essential components for professional transient protein expression in CHO-K1 cells. The eviCHO Expression Kit keeps you on the same proven platform, giving you the flexibility to adapt your approach to each project without changing your expression system.

evitria will walk participants through the composition of the eviCHO Expression Kit and the performance data behind it, explain how the workflow operates step by step, and present a comparability study on biosimilars with stable cells. The session will close with practical information on how and where to order the kit, and a live Q&A with the experts.

What's in it for you?

  • See how a ready-to-use kit with time-efficient protocol can simplify your transient protein expression workflow
  • Review the performance data behind the eviCHO expression system
  • Understand how to scale from micrograms to grams of protein
  • Learn from a comparability study
  • Find out how to order the eviCHO Expression Kit


Webinar details

English

online

December 1, 2026 | 9:00 a.m. (EST) / 3:00 p.m. (CET)

Register now

Our speakers

Registration

Register for the webinar here

Agenda

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est.

08:30 am
Registration & Light refreshments
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
09:00 am
Welcome & Introduction
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
09:10 am
Heterogeneous Catalysis in Flow Chemistry & Nickel Foam
Trevor Murray | Strategic Account Executive – Life Sciences @ Basetwo AI
10:30 am
Break
Trevor Murray | Strategic Account Executive – Life Sciences @ Basetwo AI
10:45 am
Overcoming the Selectivity Issue in a Nickel Catalyzed Batch Hydrogenation
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
11:30 am
Using Interfacial Charge Separation to Understand and Control Catalysis
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
12:15 pm
Lunch & Networking
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
01:15 pm
Heterogeneous Catalysis in CC Coupling
Maxim Radzhabov | Project Leader @ Evonik Catalysts
01:15 pm
Heterogeneous Catalysis in CC Coupling
Maxim Radzhabov | Project Leader @ Evonik Catalysts
01:15 pm
Heterogeneous Catalysis in CC Coupling
Maxim Radzhabov | Project Leader @ Evonik Catalysts
08:30 am
Registration & Light refreshments
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
09:00 am
Welcome & Introduction
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
09:10 am
Heterogeneous Catalysis in Flow Chemistry & Nickel Foam
Trevor Murray | Strategic Account Executive – Life Sciences @ Basetwo AI
10:30 am
Break
Trevor Murray | Strategic Account Executive – Life Sciences @ Basetwo AI
10:45 am
Overcoming the Selectivity Issue in a Nickel Catalyzed Batch Hydrogenation
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
11:30 am
Using Interfacial Charge Separation to Understand and Control Catalysis
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
12:15 pm
Lunch & Networking
Eric Neuffer | Drug Substance Business Head – New Business Development @ Evonik Health Care
01:15 pm
Heterogeneous Catalysis in CC Coupling
Maxim Radzhabov | Project Leader @ Evonik Catalysts
01:15 pm
Heterogeneous Catalysis in CC Coupling
Maxim Radzhabov | Project Leader @ Evonik Catalysts
01:15 pm
Heterogeneous Catalysis in CC Coupling
Maxim Radzhabov | Project Leader @ Evonik Catalysts
Time
Agenda topic 21
Speaker name | Speaker role @ Company
Time
Agenda topic 22
Speaker name | Speaker role @ Company
Time
Agenda topic 23
Speaker name | Speaker role @ Company
Time
Agenda topic 24
Speaker name | Speaker role @ Company
Time
Agenda topic 25
Speaker name | Speaker role @ Company
Time
Agenda topic 26
Speaker name | Speaker role @ Company
Time
Agenda topic 27
Speaker name | Speaker role @ Company
Time
Agenda topic 28
Speaker name | Speaker role @ Company
Time
Agenda topic 29
Speaker name | Speaker role @ Company
Time
Agenda topic 30
Speaker name | Speaker role @ Company
Time
Agenda topic 31
Speaker name | Speaker role @ Company
Time
Agenda topic 32
Speaker name | Speaker role @ Company
Time
Agenda topic 33
Speaker name | Speaker role @ Company
Time
Agenda topic 34
Speaker name | Speaker role @ Company
Time
Agenda topic 35
Speaker name | Speaker role @ Company
Time
Agenda topic 36
Speaker name | Speaker role @ Company
Time
Agenda topic 37
Speaker name | Speaker role @ Company
Time
Agenda topic 38
Speaker name | Speaker role @ Company
Time
Agenda topic 39
Speaker name | Speaker role @ Company
Time
Agenda topic 40
Speaker name | Speaker role @ Company

Disclaimer

Notice for business transactions
We assume that you are not currently or foreseeably involved in a business decision in favour of or in direct connection with the Evonik Group or, if this is the case, the decision will not be influenced by this invitation. Therefore, we do not see any concerns on our part regarding your participation. However, we would like to ask you to ensure that you are allowed to accept the invitation in accordance with the regulations that apply to you.

Note for public officials
We assume that you are not or have not been involved in any official act in favour of or in connection with the Evonik Group, either now or in the foreseeable future or in the past and therefore your participation in the event is not subject to any concerns. In addition, we ask you to ensure that your superior approves your participation or you may also accept the invitation in accordance with the rules applicable to you. By registering or participating, you confirm to us that the acceptance of this invitation is permitted according to your internal rules and that you have obtained all necessary approvals. If this is not the case, we ask you for a corresponding note.

Tax notices
Any tax liability resulting from this event will be borne by Evonik Industries AG through a flat-rate tax levy pursuant to Section 37b of the German Income Tax Act (EStG). If you are not taxable in Germany, please clarify whether you must report the invitation to your employer for taxation or whether taxation must be made via your income tax return.

Questions?

Questions

Contact Name
Contact Job Title
+49 152 29989272

  • Evonik on social media